Wall Street brokerages forecast that Altimmune, Inc. (NASDAQ:ALT) will post sales of $150,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Altimmune’s earnings, with the highest sales estimate coming in at $200,000.00 and the lowest estimate coming in at $100,000.00. Altimmune posted sales of $2.31 million in the same quarter last year, which suggests a negative year-over-year growth rate of 93.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, February 24th.
According to Zacks, analysts expect that Altimmune will report full year sales of $1.24 million for the current year, with estimates ranging from $1.10 million to $1.30 million. For the next year, analysts anticipate that the company will post sales of $7.01 million, with estimates ranging from $440,000.00 to $20.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Altimmune.
Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Monday, November 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.45). The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.11 million. Altimmune had a negative net margin of 2,431.80% and a negative return on equity of 32.83%. During the same quarter in the prior year, the company posted ($0.54) earnings per share.
A number of equities research analysts recently commented on ALT shares. JMP Securities restated a “buy” rating and set a $31.00 price target on shares of Altimmune in a research report on Tuesday, September 28th. Zacks Investment Research lowered Altimmune from a “hold” rating to a “sell” rating in a research report on Monday, November 15th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Altimmune in a research note on Monday, August 30th. B. Riley increased their price target on Altimmune from $21.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, September 7th. Finally, Piper Sandler raised their price objective on Altimmune from $16.00 to $34.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 8th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $28.50.
Several hedge funds and other institutional investors have recently made changes to their positions in ALT. Ameritas Investment Partners Inc. bought a new position in shares of Altimmune in the 2nd quarter valued at about $25,000. Legal & General Group Plc bought a new position in Altimmune during the second quarter worth about $26,000. Royal Bank of Canada grew its holdings in Altimmune by 2,032.1% during the second quarter. Royal Bank of Canada now owns 3,987 shares of the company’s stock worth $39,000 after purchasing an additional 3,800 shares during the period. Metropolitan Life Insurance Co NY bought a new position in Altimmune during the second quarter worth about $97,000. Finally, Argent Trust Co bought a new position in Altimmune during the second quarter worth about $99,000. Institutional investors own 76.57% of the company’s stock.
NASDAQ ALT opened at $9.55 on Tuesday. The firm has a market cap of $379.51 million, a PE ratio of -4.87 and a beta of 1.47. Altimmune has a one year low of $8.10 and a one year high of $24.61. The stock’s 50 day simple moving average is $10.71 and its 200 day simple moving average is $12.01.
About Altimmune
Altimmune, Inc is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is developing pemvidutide (ALT-801), a novel, GLP-1/glucagon dual agonist for the treatment of obesity and non-alcoholic steatohepatitis (NASH), and HepTcell(TM), an immunotherapeutic candidate for patients chronically infected with the hepatitis B virus (HBV).